Physician profile
Jason A Moche
NPI 1710010103
$439,384.39
in general payments reported to CMS, 2019-2025
32 companies · $116K in 2025
The $116K reported for 2025 was more than what 99% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $19K · 2021: $38K · 2022: $43K · 2023: $89K · 2024: $114K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263K · Travel and Lodging: $42K · Food and Beverage: $9,753 · Consulting Fee: $5,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262,614.67 |
| Travel and Lodging | $41,667.66 |
| Food and Beverage | $9,752.87 |
| Consulting Fee | $5,724.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $323,724.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $79,745.82 | 2019-2025 | Dupixent |
| Optinose US, INC. | $29,730.25 | 2019-2025 | |
| Acclarent, INC | $1,511.49 | 2019-2024 | Trudi Nav Cable, Acclarent Navwire |
| Aerin Medical INC. | $844.97 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $776.57 | 2019-2025 | Tezspire |
| Intersect Ent, INC. | $660.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $301.38 | 2020-2024 | Nucala, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $277.49 | 2019-2025 | |
| Incyte Corporation | $234.68 | 2022-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $185.10 | 2019-2020 | |
| Spirair, INC. | $163.93 | 2025 | |
| Genentech USA, INC. | $145.53 | 2019 | |
| Celgene Corporation | $140.00 | 2019 | |
| Medical Device Business Services, INC. | $124.18 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $115.15 | 2019-2025 | Xpress Loprofile |
| Hikma Pharmaceuticals USA | $97.41 | 2023-2024 | Ryaltris |
| Alk-Abello, INC | $93.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $79.61 | 2021-2025 | |
| Kaleo, INC. | $74.07 | 2019-2024 | Auvi-Q |
| 3b Medical, INC. | $67.84 | 2023-2025 | Luna |
| Phathom Pharmaceuticals, INC. | $50.85 | 2024 | Voquezna |
| Resmed Corp | $28.47 | 2023 | |
| Harmony Biosciences LLC | $28.23 | 2023 | Wakix |
| Integra Lifesciences Corporation | $27.72 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Aimmune Therapeutics, INC. | $26.92 | 2022 | |
| Leo Pharma INC. | $26.48 | 2024 | Adbry |
| Abbvie INC. | $25.38 | 2022 | |
| Eyevance Pharmaceuticals LLC | $23.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.70 | 2025 | |
| Lilly USA, LLC | $17.66 | 2025 | Zepbound |
| Galderma Laboratories, L.P. | $16.15 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Moche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.